Long-Term Outcomes following Intravitreal Ranibizumab for Choroidal Neovascularization Related to Nd:YAG Laser Macular Injury: A Case Report
Case Reports in Ophthalmology · 17.02.2023 · 68-74
DOI: 10.1159/000529297 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Ophthalmology, online erschienen am 17.02.2023. Verfasst von Eleni Christodoulou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Tzaneio General Hospital of Piraeus, Athens, Greece. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Choroidal neovascularization (CNV) secondary to Nd:YAG laser macular injury consists of a rare condition without standardized treatment. Herein, we present the long-term outcomes of a case with a spontaneous closure of a laser-associated macular hole that was followed by late-onset CNV and was successfully treated with intravitreal ranibizumab. A 32-year-old man suffered a macula injury in his right eye after accidental exposure to an 800-nm wave length Nd:YAG laser pulse. Ophthalmological examination demonstrated deterioration in visual acuity along with parafoveal and post-hyaloid hemorrhage. After 1 month, fundoscopy indicated the formation of a full-thickness macular hole. A close observation revealed spontaneous closure of the hole and visual improvement within the next month. One and a half year later, the patient presented with sudden visual distortion, while optical coherence tomography and fluorescein angiography disclosed the development of CNV. The patient was successfully treated with a single intravitreal injection of ranibizumab. The patient’s condition has remained stable during an 8-year follow-up period. In conclusion, laser-induced macular injury consists of an increasingly remarkable condition that may have a profound impact on visual outcomes. Our case provides insight into the potential mechanisms of Nd:YAG laser injury and its complications, indicating that CNV may occur even in the long term, while anti-vascular endothelial growth factor may help maintain stable anatomic and functional outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Tzaneio General Hospital of Piraeus, Athens, Greece.
- 2nd Ophthalmology Department, Ophthalmiatreio Eye Hospital of Athens, Athens, Greece.
- Department of Ophthalmology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
- Iris and Retina Private Practice, Ioannina, Greece.
Zitieren
APA
Christodoulou, E., Batsos, G., Christou, E. E., Gorgoli, K., Parikakis, E., Karagiannis, D., Kontomichos, L., & Stefaniotou, M. (2023). Long-Term Outcomes following Intravitreal Ranibizumab for Choroidal Neovascularization Related to Nd:YAG Laser Macular Injury: A Case Report. Case Reports in Ophthalmology, 68-74. https://doi.org/10.1159/000529297
Vancouver
Christodoulou E, Batsos G, Christou EE, Gorgoli K, Parikakis E, Karagiannis D, et al. Long-Term Outcomes following Intravitreal Ranibizumab for Choroidal Neovascularization Related to Nd:YAG Laser Macular Injury: A Case Report. Case Reports in Ophthalmology. 2023:68-74. doi:10.1159/000529297
BibTeX
@article{Christodoulou2023,
author = {Christodoulou, Eleni and Batsos, Georgios and Christou, Evita Evangelia and Gorgoli, Konstantina and Parikakis, Efstratios and Karagiannis, Dimitrios and Kontomichos, Loukas and Stefaniotou, Maria},
title = {Long-Term Outcomes following Intravitreal Ranibizumab for Choroidal Neovascularization Related to Nd:YAG Laser Macular Injury: A Case Report},
journal = {Case Reports in Ophthalmology},
year = {2023},
pages = {68--74},
doi = {10.1159/000529297}
}
EUVIMED